| 晚期非小细胞肺癌维持治疗的临床研究进展 |
| |
| 引用本文： | 张力. 晚期非小细胞肺癌维持治疗的临床研究进展[J]. 肿瘤研究与临床, 2010, 22(9): 585-588. DOI: 10.3760/cma.j.issn.1006-9801.2010.09.003 |
| |
| 作者姓名： | 张力 |
| |
| 作者单位： | 中山大学附属肿瘤医院内二科,广州,510060 |
| |
| 摘 要： | 4～6个周期含铂类的一线化疗方案是晚期非小细胞肺癌目前的标准治疗，但对一线治疗后有效和稳定的患者，如何选择安全有效的药物来拓展一线治疗疗效及带来进一步的临床获益是目前值得关注的问题。文章就以化疗和分子靶向药物作维持治疗的临床进展作一介绍。
|
| 关 键 词： | 癌 非小细胞肺 维持治疗 |
| 收稿时间： | 2010-07-12 |
Clinical research of maintenance therapy for patients with advanced non-small cell lung cancer |
| |
| ZHANG Li. Clinical research of maintenance therapy for patients with advanced non-small cell lung cancer[J]. Cancer Research and Clinic, 2010, 22(9): 585-588. DOI: 10.3760/cma.j.issn.1006-9801.2010.09.003 |
| |
| Authors: | ZHANG Li |
| |
| Affiliation: | ZHANG Li.( The Second Department of Internal Medicine, Cancer Hospital Affiliated to Sun Yat-sen University, Guangzhou 510060, China) |
| |
| Abstract: | The first-line chemotherapy with platinum-based regimens for 4 to 6 cycles is a standard care in advanced non-small cell lung cancer (NSCLC). However, for patients who got disease stabilization or maximal response after first line chemotherapy, how to choose safe and efficacy anticancer agents to extend first-line treatment and provide a better clinical benefit is deserving of more concerns currently. In this article,the clinical progress of the chemotherapy and molecular targeted agents as maintenance therapy for patients with advanced NSCLC is reviewed. |
| |
| Keywords: | Carcinoma,non-small-cell lung Maintenance therapy |
| 本文献已被 维普 万方数据 等数据库收录！ |
| 点击此处可从《肿瘤研究与临床》浏览原始摘要信息 |
|
点击此处可从《肿瘤研究与临床》下载免费的PDF全文 |
